Oncogenic RET Receptors Display Different Autophosphorylation Sites and Substrate Binding Specificities
Overview
Affiliations
The c-ret proto-oncogene encodes a receptor tyrosine kinase which plays an important role in neural crest as well as kidney development. Genetic studies have demonstrated that germ line mutations in the ret oncogene are the direct cause of multiple endocrine neoplasia (MEN) 2A and 2B, familial medullary thyroid carcinoma (FMTC), and Hirschsprung's disease. However, despite the large body of genetic and biological evidence suggesting the importance of RET in development and neoplastic processes, the signal transduction mechanisms of RET remain unknown. To begin to understand the molecular mechanisms of the disease states caused by mutations in RET, the patterns of autophosphorylation of the wild-type RET and the MEN mutants were studied using site-directed mutagenesis and phosphopeptide mapping. Among the 6 autophosphorylation sites found in the wild-type RET receptor, the MEN2B mutant lacked phosphorylation at Tyr-1096, leading to decreased Grb2 binding, while simultaneously creating a new phosphorylation site. These changes in autophosphorylation suggest that the MEN2B mutation may result in the more aggressive MEN2B phenotype by altering the receptor's signaling capabilities.
Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Pellizzari G Cancers (Basel). 2024; 16(16).
PMID: 39199650 PMC: 11352804. DOI: 10.3390/cancers16162877.
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.
PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins R, Jesus T, Cardoso L, Soares P, Vinagre J J Pers Med. 2023; 13(7).
PMID: 37511745 PMC: 10381735. DOI: 10.3390/jpm13071132.
FOXA2 and STAT5A regulate oncogenic activity of KIF5B-RET fusion.
Lee M, Shin J, Kim M, Kim J, Jung C, Kang J Am J Cancer Res. 2023; 13(2):638-653.
PMID: 36895965 PMC: 9989603.
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
Addeo A, Miranda-Morales E, den Hollander P, Friedlaender A, Sintim H, Wu J Pharmacol Ther. 2023; 242:108344.
PMID: 36632846 PMC: 10141525. DOI: 10.1016/j.pharmthera.2023.108344.